Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
06 2021
Historique:
received: 12 03 2021
revised: 09 04 2021
accepted: 12 04 2021
pubmed: 20 4 2021
medline: 1 6 2021
entrez: 19 4 2021
Statut: ppublish

Résumé

The severe acute respiratory syndrome (SARS)-CoV-2 is the pathogenetic agent of Corona Virus Induced Disease (COVID)19. The virus enters the human cells after binding to the angiotensin converting enzyme (ACE)2 receptor in target tissues. ACE2 expression is induced in response to inflammation. The colon expression of ACE2 is upregulated in patients with inflammatory bowel disease (IBD), highlighting a potential risk of intestinal inflammation in promoting viral entry in the human body. Because mechanisms that regulate ACE2 expression in the intestine are poorly understood and there is a need of anti-SARS-CoV-2 therapies, we have settled to investigate whether natural flavonoids might regulate the expression of Ace2 in intestinal models of inflammation. The results of these studies demonstrated that pelargonidin activates the Aryl hydrocarbon Receptor (AHR) in vitro and reverses intestinal inflammation caused by chronic exposure to high fat diet or to the intestinal braking-barrier agent TNBS in a AhR-dependent manner. In these two models, development of colon inflammation associated with upregulation of Ace2 mRNA expression. Colon levels of Ace2 mRNA were directly correlated with Tnf-α mRNA levels. Molecular docking studies suggested that pelargonidin binds a fatty acid binding pocket on the receptor binding domain of SARS-CoV-2 Spike protein. In vitro studies demonstrated that pelargonidin significantly reduces the binding of SARS-CoV-2 Spike protein to ACE2 and reduces the SARS-CoV-2 replication in a concentration-dependent manner. In summary, we have provided evidence that a natural flavonoid might hold potential in reducing intestinal inflammation and ACE2 induction in the inflamed colon in a AhR-dependent manner.

Identifiants

pubmed: 33872570
pii: S0006-2952(21)00160-X
doi: 10.1016/j.bcp.2021.114564
pmc: PMC8052506
pii:
doi:

Substances chimiques

Anthocyanins 0
Receptors, Aryl Hydrocarbon 0
pelargonidin 7690-51-9
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114564

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Références

World J Gastroenterol. 2017 Jul 28;23(28):5097-5114
pubmed: 28811706
Trends Immunol. 2016 Jan;37(1):17-31
pubmed: 26700314
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Food Funct. 2019 May 22;10(5):2313-2329
pubmed: 31041963
PLoS One. 2016 May 06;11(5):e0154817
pubmed: 27152519
Sci Rep. 2020 Oct 20;10(1):17772
pubmed: 33082395
Toxicol Sci. 2011 Nov;124(1):1-22
pubmed: 21908767
Obes Res Clin Pract. 2021 Jan-Feb;15(1):96-99
pubmed: 33390322
RSC Adv. 2020 Aug 13;10(50):29983-29998
pubmed: 35518212
Nature. 2012 Jul 25;487(7408):477-81
pubmed: 22837003
Gut. 2020 Jul;69(7):1335-1342
pubmed: 32303609
Gastroenterology. 2021 Feb;160(3):809-822.e7
pubmed: 33160965
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Int J Mol Med. 2015 Feb;35(2):349-57
pubmed: 25503960
Curr Protoc Microbiol. 2020 Jun;57(1):ecpmc105
pubmed: 32475066
Angew Chem Int Ed Engl. 2021 Mar 22;60(13):7098-7110
pubmed: 33469977
Crohns Colitis 360. 2020 Apr;2(2):otaa026
pubmed: 32377636
Cell. 2020 Dec 10;183(6):1732
pubmed: 33306956
Front Med (Lausanne). 2021 Jan 12;7:613475
pubmed: 33511147
Cell Res. 2017 Jan;27(1):119-129
pubmed: 28008928
Front Chem. 2020 Oct 23;8:572885
pubmed: 33195060
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Inflamm Res. 2009 Nov;58(11):819-27
pubmed: 19517214
Gastroenterology. 2020 Sep;159(3):1151-1154.e2
pubmed: 32413354
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Gut. 2020 May;69(5):841-851
pubmed: 31409604
Cell Commun Signal. 2014 Jul 24;12:48
pubmed: 25201625
J Nutr Biochem. 2016 Feb;28:103-13
pubmed: 26878787
Science. 2020 Nov 6;370(6517):725-730
pubmed: 32958580
Biochem Pharmacol. 2009 Feb 15;77(4):734-45
pubmed: 18955032
Mucosal Immunol. 2018 Jul;11(4):1024-1038
pubmed: 29626198
Nat Med. 2020 Jul;26(7):1077-1083
pubmed: 32405028
Cell Death Discov. 2020 Aug 11;6:76
pubmed: 32818075
Am J Clin Nutr. 2012 Oct;96(4):781-8
pubmed: 22914551
World J Gastroenterol. 2016 Sep 21;22(35):7868-81
pubmed: 27672284
Curr Opin Clin Nutr Metab Care. 2011 Jul;14(4):328-33
pubmed: 21587067
Eur J Epidemiol. 2020 Apr;35(4):347-354
pubmed: 32307655
J Immunol. 2017 Jul 15;199(2):718-733
pubmed: 28607110
Nutrients. 2019 Aug 07;11(8):
pubmed: 31394746
J Crohns Colitis. 2021 Mar 5;15(3):485-498
pubmed: 32915959
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Int J Obes (Lond). 2020 Aug;44(8):1790-1792
pubmed: 32409680
PLoS One. 2016 Mar 10;11(3):e0150861
pubmed: 26963721
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4557-76
pubmed: 25197329
Nat Commun. 2017 Apr 10;8:15092
pubmed: 28393837
Immunobiology. 1995 Jul;193(2-4):193-203
pubmed: 8530143
J Comput Chem. 2005 Dec;26(16):1752-80
pubmed: 16211539
J Comput Aided Mol Des. 2007 Dec;21(12):681-91
pubmed: 17899391
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
J Autoimmun. 2020 Aug;112:102463
pubmed: 32303424
Sci Rep. 2017 Feb 16;7:42801
pubmed: 28202906
J Med Chem. 2004 Mar 25;47(7):1750-9
pubmed: 15027866
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
J Med Virol. 2020 Nov;92(11):2693-2701
pubmed: 32497323
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):1-12
pubmed: 33037944

Auteurs

Michele Biagioli (M)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Silvia Marchianò (S)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Rosalinda Roselli (R)

University of Naples Federico II, Department of Pharmacy, Naples, Italy.

Cristina Di Giorgio (C)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Rachele Bellini (R)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Martina Bordoni (M)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Anna Gidari (A)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Samuele Sabbatini (S)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Daniela Francisci (D)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Bianca Fiorillo (B)

University of Naples Federico II, Department of Pharmacy, Naples, Italy.

Bruno Catalanotti (B)

University of Naples Federico II, Department of Pharmacy, Naples, Italy.

Eleonora Distrutti (E)

SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, Perugia, Italy.

Adriana Carino (A)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy.

Angela Zampella (A)

University of Naples Federico II, Department of Pharmacy, Naples, Italy.

Gabriele Costantino (G)

Department of Food and Drugs, University of Parma, Parma, Italy.

Stefano Fiorucci (S)

Dipartimento di Medicina e Chirurgia, Università di Perugia, Perugia, Italy. Electronic address: stefano.fiorucci@unipg.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH